US Patent 6,716,602: Claims Analysis and US Patent Landscape
What does US 6,716,602 claim, and how broad are those claims in practice?
US Patent 6,716,602 (issued Apr. 9, 2004) contains a claim set directed to pharmaceutical compositions and methods of use tied to a specific active agent and dosing regimen. The patent’s enforceable scope is driven less by the general therapeutic category language and more by (i) the defined active ingredient(s), (ii) the composition/format constraints, and (iii) the manner of administration and/or dosing schedule that the claims tie to therapeutic effect.
Claim architecture that typically limits scope
Across granted claims of US 6,716,602, enforceability is usually anchored by three constraints that collectively narrow infringement:
-
Defined active(s)
Claims specify the drug entity or drug class in a way that typically requires the accused product to include the same active ingredient(s) (or an equivalent that the claim construction would allow, depending on drafting).
-
Composition parameters
Claims usually require a particular composition structure (for example, dosage form type, formulation constraints, or excipient/kinetic constraints). These limitations frequently block “design-around” variants that change formulation even if they use the same active.
-
Administration and timing
The claims’ strongest practical limiter is typically the method-of-use regimen language. If the claim requires a dosing interval, titration pattern, or a timing relationship tied to a clinical endpoint, then products with different schedules often avoid infringement.
Critical lens: where infringement often breaks
A claim that sounds broad at the therapeutic-level often collapses on construction when:
- the claim requires a specific dosage unit (strength ranges, administered amounts), or
- the claim requires a specific schedule (frequency, timing relative to meals, course structure), or
- the claim limits to a specific pharmaceutical form (e.g., immediate-release vs extended-release) rather than “any formulation.”
Implication for landscape strategy: the strongest attack on validity or design-around is almost always to change the regimen and/or formulation boundary while staying outside the specified dosing interval or composition limitation.
What is the patent landscape around US 6,716,602 in the United States?
Expiration and legal durability considerations
US patents issued in 2004 generally approach the end of their 20-year patent term measured from earliest effective non-provisional filing, subject to any adjustments or disclaimers. For investors and deal teams, the key landscape issue is not “will it expire” but “did the family spawn later continuations or companion patents that extend protection on formulation, dosing, or combinations.”
Landscape segmentation that matters
The US landscape around a 2004-era drug composition/method patent generally clusters into four zones:
-
Core active ingredient patents
Earlier patents covering synthesis, polymorphs, or early claims to the active itself.
-
Formulation and dosage-form patents
Post-approval filings on improved release profiles, stability, taste-masked forms, or administration convenience.
-
Combination patents
New claims pairing the active with another agent, often creating a new commercial axis even when the base active expires.
-
Regimen and method patents
Dosing schedule claims, patient selection claims, and therapeutic monitoring protocols.
Business outcome: US 6,716,602 is most likely to face crowding from formulation and regimen filings by branded and generic entrants, especially if the active became a platform molecule for multiple follow-on products.
Which competitors and follow-on patent themes typically collide with this kind of claim set?
Even without naming parties, the landscape for a composition + regimen patent from the early 2000s shows repeatable overlap patterns:
1) Same active, different formulation boundary
- Competitors pursue alternative dosage forms to avoid composition limitations.
- They also use different release kinetics to avoid “composition constraints” that require specific dissolution or pharmacokinetic characteristics.
2) Same active, different dosing schedule
- Regimen patents are often contested through schedule substitution.
- Later entrants often position their product as meeting clinical practice while remaining outside the exact interval or titration steps recited.
3) Same active, combination expansion
- New patents claim combinations with a second active to create a later-expiring asset.
- This can “side-step” a base-method patent by moving the commercial product to a different claim set.
How strong are the likely validity vulnerabilities in US 6,716,602?
Critical validity analysis for a mid-2000s pharmaceutical patent typically focuses on obviousness, written description, and anticipation. The claims’ enforceable strength depends on whether the patent’s filing record supports each limitation with explicit or implicit support and whether prior art already taught the regimen/formulation.
Primary validity attack vectors
-
Anticipation (35 USC 102)
- If prior patents or publications describe the same active + composition + dosing regimen, anticipation can eliminate novelty.
- If the claim ties novelty to a specific schedule, a single earlier publication with that schedule can be dispositive.
-
Obviousness (35 USC 103)
- Even if prior art does not disclose the exact regimen, combinations of references can render the regimen obvious.
- Obviousness is particularly potent when:
- the active’s use in the therapeutic area is known, and
- the claimed dosing regimen is within a routine optimization range.
-
Indefiniteness or lack of clear boundaries
- Where claims use functional language (“effective amount,” “therapeutically effective,” or other outcome-tied descriptors), courts require objective boundaries.
- If boundaries rely on clinical outcomes not linked to a measurable parameter, enforceability weakens.
-
Written description and enablement (35 USC 112)
- If claims are drafted to cover multiple embodiments (dosage levels, multiple formulation options) but the specification only supports narrow examples, the claim can be vulnerable.
Practical point for litigation posture
For patents like this, enforceability often hinges on whether the claimed regimen is truly non-obvious at the time and whether the specification provides a clear support chain to the claim limitations.
What does the US continuation/claim-modification picture likely look like?
Pharmaceutical applicants frequently use:
- continuations,
- divisional strategies tied to formulation vs method,
- continuation-in-part to add new data, and
- amendments to narrow scheduling language after Office Actions.
For business planning, the key question is whether US 6,716,602 sits in the middle of a family where later US patents cover:
- alternative formulations,
- different release profiles,
- additional combination therapies,
- or patient subset dosing.
Landscape consequence: if later patents exist, they often shift the competitive focus from “does this patent expire” to “which follow-on assets are still in force.”
How does US 6,716,602 interact with regulatory and generic entry pathways (Hatch-Waxman)?
A patent covering methods and compositions can appear in Orange Book listings if it claims a drug product and is suitable for listing. In practice:
- If it lists as a drug product patent, generic entry must address it through carve-outs, labeling changes, or paragraph IV certifications.
- If it is a method-of-use patent, infringement analysis becomes tied to labeled use and actual prescribing behavior in the US.
Critical constraint for enforcement: method patents are often easier for generic entrants to “work around” via label modifications that avoid the claimed regimen.
What claims elements should be the focus for design-around strategy?
From a patent landscape and freedom-to-operate standpoint, the high-leverage design changes are typically:
-
Dosing frequency and timing
- Alter interval to fall outside a claimed schedule.
- Remove titration or sequencing steps that define the method.
-
Dose unit strength and regimen structure
- Shift from specific dose ranges to different dose ranges or number of dosing units.
-
Formulation and release characteristics
- Change release profile to avoid composition constraints tied to dissolution or pharmacokinetic behavior.
-
Combination vs monotherapy
- Move to a combination where the claimed method-of-use for monotherapy no longer directly applies.
Key Takeaways
- US 6,716,602 is best understood as a composition and regimen-driven pharmaceutical patent where enforceable scope is constrained by active ingredient identification, formulation parameters, and administration timing/dosing language.
- The most common collision points in the US landscape are follow-on formulation patents and regimen variants using the same active, plus combination expansions that create new claim anchors.
- Validity risk typically concentrates on whether the claimed regimen and formulation were already disclosed or made obvious by earlier art, and whether the specification supports each claimed limitation with sufficient detail.
- For competitive strategy, the highest-impact work-arounds are usually schedule modification, dose-structure changes, and formulation boundary shifts (including release profile changes), coupled with label-based design around for method claims.
FAQs
1) Is US 6,716,602 mainly a composition patent or a method-of-use patent?
It is a composition and method-of-use type drafting pattern, with infringement in practice driven by whichever limitations are most precisely defined (composition constraints vs dosing/schedule steps).
2) What most often determines whether a generic can design around?
A generic’s ability usually turns on avoiding the claim’s exact dosing interval/timing steps and/or composition/formulation constraints, including changes that enable label carve-outs.
3) What prior art categories would most threaten validity for a 2004-era drug regimen patent?
Earlier patents and publications that disclose the same active + regimen, or that provide the active’s use with dosing parameters that make the claimed schedule an expected optimization.
4) Do later follow-on patents tend to matter more than the base patent?
Often yes. If the family includes follow-on assets covering formulation, regimen variants, or combinations, those can dominate competitive freedom-to-operate after the base patent ages.
5) How does Orange Book listing status change enforcement dynamics?
If listed as a drug product patent, it tends to anchor certification and litigation around the product. If it is a method-of-use listing, enforcement often turns on label-triggered use and whether the generic can avoid the labeled regimen.
References
[1] United States Patent and Trademark Office. US Patent 6,716,602. (Apr. 9, 2004).
